OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (TBIO), (NASDAQ: TBIO) today reported financial results for the second quarter ended June 30, 2016, and provided a business update.
Second Quarter Financial Results from Continuing Operations
Net sales for the second quarter of 2016 were $0.5 million as compared with $0.4 million for the same period in 2015. Sales of the Company’s contract laboratory services were flat year over year. The slight increase in total sales for the current year reflects increased oncology and grant revenues.
Second Quarter Financial Results from Continuing Operations
Net sales for the second quarter of 2016 were $0.5 million as compared with $0.4 million for the same period in 2015. Sales of the Company’s contract laboratory services were flat year over year. The slight increase in total sales for the current year reflects increased oncology and grant revenues.
